MAP1A and urinary bladder carcinoma: To further confirm whether single-gene MAP1A is a potential monitoring biomarker for immunotherapy in bladder cancer, TIMER2.0 and GEPIA databases were used for correlation analysis of immune checkpoint PDL-1/PD1, CTLA4 related gene CD274, PDCD1, and CTLA4.